PBLA RSI Chart
Last 7 days
-60.4%
Last 30 days
-15.4%
Last 90 days
-64.8%
Trailing 12 Months
-99.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2018 | 0 | 0 | 0 | 0 |
2017 | 0 | 3.0K | 2.0K | 1.0K |
2016 | 7.0K | 5.0K | 5.0K | 4.0K |
2015 | 0 | 0 | 0 | 8.0K |
2014 | 0 | 0 | 0 | 0 |
2013 | 1.2M | 1.1M | 1.0M | 973.8K |
2012 | 0 | 0 | 0 | 1.2M |
2011 | 0 | 0 | 0 | 699.8K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 08, 2023 | goldman sachs group inc | sold | -51,740 | 0.71 | -72,874 | - |
Sep 12, 2023 | jacob jeffrey e. | gifted | - | - | -275 | - |
Jan 30, 2023 | simpson jennifer k. | bought | - | - | 4,444 | president and ceo |
Jan 30, 2023 | horvath susan | bought | - | - | 4,444 | v.p. of finance & cfo |
Oct 04, 2022 | jacob jeffrey e. | bought | - | - | 33,000 | - |
Oct 04, 2022 | cullen michael t. | bought | - | - | 165,000 | - |
Oct 04, 2022 | schemel donald robert | bought | - | - | 200,000 | - |
May 25, 2021 | mathiesen jeffrey s | acquired | - | - | 4,316 | - |
May 25, 2021 | cullen michael t. | acquired | - | - | 4,316 | - |
May 25, 2021 | schemel donald robert | acquired | - | - | 4,316 | - |
Which funds bought or sold PBLA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -31,303 | - | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | sold off | -100 | -448,588 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -10,695 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -13,739 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -2.00 | - | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -9.00 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | sold off | -100 | -14,535 | - | -% |
May 13, 2024 | HRT FINANCIAL LP | sold off | -100 | -34,000 | - | -% |
May 10, 2024 | JPMORGAN CHASE & CO | sold off | -100 | -11,393 | - | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | sold off | -100 | -63.00 | - | -% |
Unveiling Panbela Therapeutics Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Panbela Therapeutics Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Panbela Therapeutics Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2014Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 |
Revenue | 141.7% | 29.00 | 12.00 | 10.00 | 34.00 | 59.00 | 83.00 | 42.00 | - | 1.00 | 1.00 | 3.00 | - | 3.00 | 99.00 | 195 | 291 | 296 | 300 | 305 | 246 | 204 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 142 | 146 | 58.00 | 142 | 154 | 241 | -107 | 230 | 222 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 149 | 141 | 455 | 150 | 155 | 1.00 | 405 | 16.00 | -3.51 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 418 | 70.00 | 40.00 |
S&GA Expenses | -28.6% | 467 | 654 | 658 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | 1.8% | 450 | 442 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -99.8% | 3.00 | 1,288 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | 30.4% | -55.00 | -79.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 61.8% | -980 | -2,564 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 62.8% | -925 | -2,487 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -10.8% | 10,527 | 11,802 | 10,628 | 19,551 | 16,475 | 4,978 | 4,867 | 6,557 | 11,088 | 12,872 | 14,802 | 7,295 | 8,894 | 9,813 | 11,485 | 3,322 | 2,136 | 3,144 | 3,820 | 1,339 | 1,911 |
Current Assets | -41.7% | 1,785 | 3,060 | 1,886 | 10,809 | 7,833 | 1,777 | 1,766 | 3,456 | 7,933 | 12,279 | 14,749 | 7,240 | 8,839 | 9,757 | 11,433 | 3,272 | 2,091 | 3,093 | 3,771 | 1,288 | 1,860 |
Cash Equivalents | -89.9% | 262 | 2,600 | 900 | 7,200 | 5,235 | 1,285 | 941 | 2,530 | 7,400 | 11,867 | 14,072 | 6,405 | 8,098 | 9,022 | 10,870 | 2,265 | 1,296 | 2,449 | 3,377 | 721 | 1,379 |
Liabilities | -17.0% | 13,713 | 16,512 | 13,111 | 14,749 | 13,940 | 13,027 | 13,146 | 11,395 | 7,028 | 2,660 | 2,336 | 2,013 | 1,689 | 1,365 | - | - | - | 1,759 | 1,431 | 1,456 | 1,543 |
Current Liabilities | -14.6% | 10,519 | 12,318 | 8,917 | 10,555 | 9,746 | 7,833 | 7,952 | 6,201 | 4,507 | 2,660 | 1,339 | 1,393 | 1,310 | 1,365 | 1,936 | 1,722 | 1,412 | 1,759 | 689 | 714 | 2,499 |
Long Term Debt | -23.8% | 3,194 | 4,194 | 4,194 | 4,194 | 4,194 | 5,194 | 5,194 | 5,194 | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 232 | 259 |
LT Debt, Non Current | -100.0% | - | 4,194 | 4,194 | 4,194 | 4,194 | 5,194 | 5,194 | 5,194 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 32.1% | -3,200 | -4,710 | - | 4,796 | 2,525 | -8,049 | - | - | 6,582 | 10,213 | 13,463 | 5,889 | 7,584 | 8,447 | 9,549 | 1,600 | 724 | 1,384 | 2,389 | - | - |
Retained Earnings | -5.7% | -132,617 | -125,500 | -109,900 | -102,046 | -96,207 | -91,094 | -86,359 | -82,000 | -59,800 | -56,161 | -52,600 | -50,500 | -48,283 | -46,026 | -45,146 | -43,475 | -43,056 | -41,258 | -40,284 | -38,910 | -36,639 |
Additional Paid-In Capital | 6.8% | 128,223 | 120,043 | 106,026 | 105,855 | 97,804 | 82,286 | 76,686 | 76,451 | 66,561 | 66,240 | 65,891 | 56,506 | 56,142 | 54,848 | 54,544 | 44,681 | 42,671 | 42,331 | 42,164 | 38,487 | 35,795 |
Shares Outstanding | 911.4% | 4,855 | 480 | 150 | 131 | 27.00 | 2.00 | 855.35* | 600.15* | 560.02* | 10.00 | 463.45* | 420.54* | 411.98* | 402.68* | - | - | - | - | - | - | - |
Float | - | - | - | - | 6,004 | - | - | - | 11,426 | - | - | - | 33,799 | - | - | - | 30,196 | - | - | - | 9,496 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -205.2% | -9,400 | -3,080 | -6,677 | -5,741 | -9,751 | -5,003 | -1,593 | -4,197 | -4,483 | -2,228 | -1,359 | -1,693 | -1,965 | -1,113 | -765 | -856 | -1,120 | -872 | -453 | -631 | -783 |
Share Based Compensation | -16.9% | 103 | 124 | 190 | 329 | 180 | 231 | 230 | 293 | 334 | 336 | 335 | 364 | 252 | 236 | 593 | 264 | 112 | 135 | 536 | 412 | 10.00 |
Cashflow From Investing | - | - | - | 400 | - | - | - | -1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | 49.3% | 7,082 | 4,742 | - | 7,700 | 13,700 | 5,349 | 5.00 | - | - | 1.00 | 9,053 | - | 1,042 | -711 | 9,359 | 1,822 | -26.00 | -61.00 | 3,115 | -28.00 | 758 |
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
General and administrative | $ 1,204 | $ 1,352 |
Research and development | 5,522 | 3,508 |
Operating loss | (6,726) | (4,860) |
Other income (expense): | ||
Interest income | 0 | 16 |
Interest expense | (63) | (102) |
Other expense | (469) | (167) |
Total other expense | (532) | (253) |
Loss before income tax benefit | (7,258) | (5,113) |
Income tax benefit | 138 | 0 |
Net loss | (7,120) | (5,113) |
Foreign currency translation adjustment | 459 | 163 |
Comprehensive loss | $ (6,661) | $ (4,950) |
Basic and diluted net loss per share (in dollars per share) | $ (2.28) | $ (392.76) |
Weighted average shares outstanding - basic and diluted (in shares) | 3,125,835 | 13,018 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 262,000 | $ 2,578,000 |
Prepaid expenses and other current assets | 1,210,000 | 299,000 |
Income tax receivable | 313,000 | 183,000 |
Total current assets | 1,785,000 | 3,060,000 |
Other non-current assets | 8,742,000 | 8,742,000 |
Total assets | 10,527,000 | 11,802,000 |
Current liabilities: | ||
Accounts payable | 8,506,000 | 9,939,000 |
Accrued expenses | 979,000 | 1,141,000 |
Accrued interest payable | 34,000 | 238,000 |
Debt, current portion | 1,000,000 | 1,000,000 |
Total current liabilities | 10,519,000 | 12,318,000 |
Debt, net of current portion | 3,194,000 | 4,194,000 |
Total non-current liabilities | 3,194,000 | 4,194,000 |
Total liabilities | 13,713,000 | 16,512,000 |
Stockholders' deficit: | ||
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 authorized; 4,854,931 and 480,095 issued as of March 31, 2024 and December 31, 2023 respectively; 4,854,861 and 480,025 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 5,000 | 0 |
Treasury Stock at cost; 70 shares at both of March 31, 2024 and December 31, 2023 | (1,000) | (1,000) |
Additional paid-in capital | 128,223,000 | 120,043,000 |
Accumulated deficit | (132,617,000) | (125,497,000) |
Accumulated comprehensive income | 1,204,000 | 745,000 |
Total stockholders' deficit | (3,186,000) | (4,710,000) |
Total liabilities and stockholders' deficit | $ 10,527,000 | $ 11,802,000 |